Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

Overview of attention for article published in Cancer (0008543X), June 2011

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

patent: 5 patents

Readers on

mendeley: 51 Mendeley

So far, Altmetric has seen 5 patents that reference this research output.

GENETICALLY MODIFIED NATURAL KILLER CELLS AND METHODS OF USE THEREOF

Application WO-2022104109-A1

World Intellectual Property Organisation (WIPO)

19 May 2022

Nucleic acid medicine and its use

Application JP-WO2021002359-A1

Japan

13 Sep 2021

NUCLEIC ACID DRUG AND USE THEREOF

Application WO-2021157730-A1

World Intellectual Property Organisation (WIPO)

12 Aug 2021

NUCLEIC ACID DRUG AND USE THEREOF

Application WO-2021002359-A1

World Intellectual Property Organisation (WIPO)

07 Jan 2021

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 1 additional patents.